THE WOODLANDS, Texas, March 13, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today additional data on XERMELO’s ® (telotristat ethyl) antiproliferative effects in ...

As with other drugs, Xermelo (telotristat ethyl) can cause side effects. These include nausea and headache. If side effects of Xermelo become difficult to tolerate, talk with your doctor or pharmacist ...

Sorafenib as bridging therapy in patients with intermediate hepatocellular carcinoma. This is an ASCO Meeting Abstract from the 2012 ASCO Annual Meeting I. This abstract does not include a full text ...

Carcinoid syndrome is a rare condition that occurs in patients with gastrointestinal tumors. These patients secrete an excessive amount of serotonin, which can lead to symptoms like frequent diarrhea, ...

Xermelo (telotristat ethyl) can cause side effects ranging from mild to serious. More common side effects include nausea and headache. If side effects from Xermelo become difficult to tolerate, talk ...

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Amryt’s AMYT lead drug Mycapssa for the treatment of carcinoid syndrome. Carcinoid syndrome (CS) is the most common ...

SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced three abstracts from its clinical development programs will be presented at the upcoming ...

Amryt Receives Orphan Drug Designation from the FDA for Mycapssa® (oral octreotide) for the Treatment of Carcinoid Syndrome DUBLIN, Ireland, and Boston MA, July 14, 2022, Amryt (Nasdaq: AMYT), a ...

Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors. Lexicon Pharmaceuticals, a biopharmaceutical company centered on the discovery and development of breakthrough ...

Xermelo (telotristat ethyl) is an oral tablet prescribed for adults to treat diarrhea related to carcinoid syndrome. This drug can interact with other medications. For example, Xermelo can interact ...

DUBLIN, Ireland, and Boston MA, July 14, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company focused on acquiring, developing and commercializing novel treatments for rare ...